Allogeneic hematopoietic stem cell ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis.
Auteur(s) :
Berning, Philipp [Auteur]
University Hospital Münster - Universitaetsklinikum Muenster [Germany] [UKM]
Schmitz, Norbert [Auteur]
University Hospital Münster - Universitaetsklinikum Muenster [Germany] [UKM]
Ngoya, Maud [Auteur]
CHU Saint-Antoine [AP-HP]
Finel, Hervé [Auteur]
CHU Saint-Antoine [AP-HP]
Boumendil, Ariane [Auteur]
CHU Saint-Antoine [AP-HP]
Wang, Fengrong [Auteur]
Peking University [Beijing]
Huang, Xiao-Jun [Auteur]
Peking University [Beijing]
Hermine, Olivier [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Philippe, Laure [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Couronné, Lucile [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Jaccard, Arnaud [Auteur]
Hôpital Dupuytren [CHU Limoges]
Liu, Daihong [Auteur]
Wu, Depei [Auteur]
Soochow University
Reinhardt, Hans Christian [Auteur]
Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
Chalandon, Yves [Auteur]
Hôpitaux Universitaires de Genève [HUG]
Wagner-Drouet, Eva [Auteur]
University Medical Center [Mainz]
Kwon, Mi [Auteur]
Hospital General Universitario "Gregorio Marañón" [Madrid]
Zhang, Xiaoling [Auteur]
City University of Hong Kong [Hong Kong] [CUHK]
Carpenter, Ben [Auteur]
University College London Hospitals [UCLH]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Wulf, Gerald [Auteur]
Georg-August-University = Georg-August-Universität Göttingen
López-Jiménez, Javier [Auteur]
Hospital Universitario Ramón y Cajal [Madrid]
Sanz, Jaime [Auteur]
Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
Labussière-Wallet, Hélène [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Shimoni, Avichai [Auteur]
Chaim Sheba Medical Center
Dreger, Peter [Auteur]
Heidelberg University Hospital [Heidelberg]
Sureda, Anna [Auteur]
Universitat de Barcelona [UB]
Kim, Won Seog [Auteur]
Samsung Medical Center Sungkyunkwan University School of Medicine
Glass, Bertram [Auteur]
Helios Klinikum [Erfurt]
University Hospital Münster - Universitaetsklinikum Muenster [Germany] [UKM]
Schmitz, Norbert [Auteur]
University Hospital Münster - Universitaetsklinikum Muenster [Germany] [UKM]
Ngoya, Maud [Auteur]
CHU Saint-Antoine [AP-HP]
Finel, Hervé [Auteur]
CHU Saint-Antoine [AP-HP]
Boumendil, Ariane [Auteur]
CHU Saint-Antoine [AP-HP]
Wang, Fengrong [Auteur]
Peking University [Beijing]
Huang, Xiao-Jun [Auteur]
Peking University [Beijing]
Hermine, Olivier [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Philippe, Laure [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Couronné, Lucile [Auteur]
Hôpital Necker - Enfants Malades [AP-HP]
Jaccard, Arnaud [Auteur]
Hôpital Dupuytren [CHU Limoges]
Liu, Daihong [Auteur]
Wu, Depei [Auteur]
Soochow University
Reinhardt, Hans Christian [Auteur]
Universität Duisburg-Essen = University of Duisburg-Essen [Essen]
Chalandon, Yves [Auteur]
Hôpitaux Universitaires de Genève [HUG]
Wagner-Drouet, Eva [Auteur]
University Medical Center [Mainz]
Kwon, Mi [Auteur]
Hospital General Universitario "Gregorio Marañón" [Madrid]
Zhang, Xiaoling [Auteur]
City University of Hong Kong [Hong Kong] [CUHK]
Carpenter, Ben [Auteur]
University College London Hospitals [UCLH]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Wulf, Gerald [Auteur]
Georg-August-University = Georg-August-Universität Göttingen
López-Jiménez, Javier [Auteur]
Hospital Universitario Ramón y Cajal [Madrid]
Sanz, Jaime [Auteur]
Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
Labussière-Wallet, Hélène [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Shimoni, Avichai [Auteur]
Chaim Sheba Medical Center
Dreger, Peter [Auteur]
Heidelberg University Hospital [Heidelberg]
Sureda, Anna [Auteur]
Universitat de Barcelona [UB]
Kim, Won Seog [Auteur]
Samsung Medical Center Sungkyunkwan University School of Medicine
Glass, Bertram [Auteur]
Helios Klinikum [Erfurt]
Titre de la revue :
Leukemia
Nom court de la revue :
Leukemia
Date de publication :
2023-05-10
ISSN :
1476-5551
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Natural killer/T-cell lymphomas (NKTCL) represent rare and aggressive lymphoid malignancies. Patients (pts) with relapsed/refractory disease after Asparaginase (ASPA)-based chemotherapy have a dismal prognosis. To better ...
Lire la suite >Natural killer/T-cell lymphomas (NKTCL) represent rare and aggressive lymphoid malignancies. Patients (pts) with relapsed/refractory disease after Asparaginase (ASPA)-based chemotherapy have a dismal prognosis. To better define the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT), we conducted a retrospective analysis of data shared with the European Society for Blood and Marrow Transplantation (EBMT) and cooperating Asian centers. We identified 135 pts who received allo-HSCT between 2010 and 2020. Median age was 43.4 years at allo-HSCT, 68.1% were male. Ninety-seven pts (71.9 %) were European, 38 pts (28.1%) Asian. High Prognostic Index for NKTCL (PINK) scores were reported for 44.4%; 76.3% had >1 treatment, 20.7% previous auto-HSCT, and 74.1% ASPA-containing regimens prior to allo-HSCT. Most (79.3%) pts were transplanted in CR/PR. With a median follow-up of 4.8 years, 3-year progression-free(PFS) and overall survival were 48.6% (95%-CI:39.5–57%) and 55.6% (95%-CI:46.5–63.8%). Non-relapse mortality at 1 year was 14.8% (95%-CI:9.3–21.5%) and 1-year relapse incidence 29.6% (95%-CI:21.9–37.6%). In multivariate analyses, shorter time interval (0–12 months) between diagnosis and allo-HSCT [HR = 2.12 (95%-CI:1.03–4.34); P = 0.04] and transplantation not in CR/PR [HR = 2.20 (95%-CI:0.98–4.95); P = 0.056] reduced PFS. Programmed cell death protein 1(PD-1/PD-L1) treatment before HSCT neither increased GVHD nor impacted survival. We demonstrate that allo-HSCT can achieve long-term survival in approximately half of pts allografted for NKTCL.Lire moins >
Lire la suite >Natural killer/T-cell lymphomas (NKTCL) represent rare and aggressive lymphoid malignancies. Patients (pts) with relapsed/refractory disease after Asparaginase (ASPA)-based chemotherapy have a dismal prognosis. To better define the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT), we conducted a retrospective analysis of data shared with the European Society for Blood and Marrow Transplantation (EBMT) and cooperating Asian centers. We identified 135 pts who received allo-HSCT between 2010 and 2020. Median age was 43.4 years at allo-HSCT, 68.1% were male. Ninety-seven pts (71.9 %) were European, 38 pts (28.1%) Asian. High Prognostic Index for NKTCL (PINK) scores were reported for 44.4%; 76.3% had >1 treatment, 20.7% previous auto-HSCT, and 74.1% ASPA-containing regimens prior to allo-HSCT. Most (79.3%) pts were transplanted in CR/PR. With a median follow-up of 4.8 years, 3-year progression-free(PFS) and overall survival were 48.6% (95%-CI:39.5–57%) and 55.6% (95%-CI:46.5–63.8%). Non-relapse mortality at 1 year was 14.8% (95%-CI:9.3–21.5%) and 1-year relapse incidence 29.6% (95%-CI:21.9–37.6%). In multivariate analyses, shorter time interval (0–12 months) between diagnosis and allo-HSCT [HR = 2.12 (95%-CI:1.03–4.34); P = 0.04] and transplantation not in CR/PR [HR = 2.20 (95%-CI:0.98–4.95); P = 0.056] reduced PFS. Programmed cell death protein 1(PD-1/PD-L1) treatment before HSCT neither increased GVHD nor impacted survival. We demonstrate that allo-HSCT can achieve long-term survival in approximately half of pts allografted for NKTCL.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Date de dépôt :
2024-01-11T22:47:28Z
2024-03-06T12:54:33Z
2024-03-06T12:54:33Z
Fichiers
- s41375-023-01924-x.pdf
- Non spécifié
- Accès libre
- Accéder au document